PolyNovo makes NovoSorb BTM, a proprietary synthetic scaffold that regrows skin in burn and wound patients — the only biodegradable single-stage product of its kind. At A$0.92 versus our fair value of A$0.41, the stock is 55% overpriced. The core problem is straightforward: the market is applying a US cost of capital to an ASX-listed company, and once you correct for that, the premium largely evaporates — leaving a good business at the wrong price.

The best fit for PNV is the thematic investor with a 2–3 year horizon and high risk tolerance. The investment case is built on a specific regulatory catalyst — CMS outpatient access — and a structural shift in how US hospitals procure wound care products. That thesis is coherent and evidenced. The difficulty is that at A$0.92, the market has already priced the optimistic outcome, leaving little cushion if the catalyst is delayed or denied.

PolyNovo manufactures NovoSorb BTM, a synthetic biodegradable scaffold used in burns, complex wounds, and reconstructive surgery. The company sells direct to hospitals, earning nearly all revenue from product sales in the US (75%) and internationally (25%). BARDA, a US government defence health agency, has historically funded some R&D — that contract is winding down and will be nil from FY27.

The first half of FY26 showed commercial revenue growing 26% to A$68m, with the new MTX product accelerating sharply. EBITDA margins are expanding as the cost base scales more slowly than revenue — employee cost growth slowed from 29% to 12%, the clearest evidence yet that operating leverage is arriving. Free cash flow turned positive for the first time.

The investment case rests on three pillars: a proprietary product with no direct synthetic equivalent, a compounding clinical evidence base that takes competitors years to replicate, and a regulatory environment that is actively favouring PNV's approach over higher-cost biological alternatives. The risks that matter most are a patent expiry in March 2028 with no disclosed succession strategy, and a CMS outpatient coverage decision later this year that is genuinely binary.

At A$0.92 versus our fair value of A$0.41, the stock is 55% overvalued.

What happened?

PNV's first-half FY26 result was solid beneath the headline noise. A R&D lab fire wrote off A$4.4m in assets and a deliberate manufacturing slowdown (to prepare for FDA approval work) suppressed EBITDA by A$3.65m. Strip those out and underlying momentum was strong: commercial revenue grew 26%, new accounts continued to open, and the MTX wound product grew 175%. More importantly, employee cost growth slowed sharply — the first tangible evidence that the fixed cost base is beginning to work for shareholders rather than against them.

Key Metrics

What's next?

Three catalysts define the next 24 months. The most important is the CMS outpatient coverage decision for BTM, expected in the third or fourth quarter of calendar 2026. Approval would open a market segment currently inaccessible and is worth roughly A$0.08 per share on our estimates. The second is the HCPCS reimbursement code for MTX — the application has not yet been submitted, and approval is 18–24 months away at minimum. Third, the new Port Melbourne facility becomes operational in July 2026, removing a manufacturing constraint that has held back output.

The margin story is simpler. Capex halves from FY27 as the facility build completes, converting operating cash flow directly into free cash flow. EBITDA margins should reach 15% by FY28 as the employee cost ratio — which peaked near 59% of revenue — continues to compress. The key monitoring number is whether that ratio stays on its current declining path. Any re-acceleration would signal the operating leverage thesis is stalling.

The most important thing to understand about PNV's valuation is where the gap comes from. Most of the 55% premium is not a disagreement about the business — it is a disagreement about discount rates. PNV is listed on the ASX, so we apply a 13% cost of capital derived from Australian interest rates and market risk. US-listed peers trade on roughly 9%. At 9%, our fair value rises to A$0.65–0.70, closing most of the gap. The market is implicitly treating PNV as a US company; we are treating it as an Australian one. Both views are defensible.

The risk that keeps us cautious is the patent expiry in March 2028. PNV's core IP protection disappears in roughly 25 months, and management has disclosed no strategy for what happens next. The clinical evidence base and manufacturing know-how will persist — MiMedx has maintained pricing power for decades post-patent — but the uncertainty is real and unaddressed. If generic synthetic competitors enter and compress terminal margins by 300–400 basis points, fair value falls by roughly A$0.06 per share. Combined with a delayed CMS decision, that scenario implies a share price below A$0.25.